FY2025 EPS Estimates for Cabaletta Bio Increased by Analyst

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Cabaletta Bio in a research note issued to investors on Tuesday, April 1st. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($1.22) for the year, up from their previous forecast of ($2.19). The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share.

Other research analysts have also recently issued reports about the stock. Guggenheim reiterated a "buy" rating and issued a $23.00 target price on shares of Cabaletta Bio in a research note on Tuesday, April 1st. UBS Group dropped their price objective on Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Evercore ISI lowered Cabaletta Bio from an "outperform" rating to an "inline" rating and reduced their price objective for the company from $15.00 to $6.00 in a report on Friday, December 20th. Wells Fargo & Company lowered their target price on Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $25.00 price target on shares of Cabaletta Bio in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Cabaletta Bio presently has an average rating of "Buy" and a consensus target price of $21.00.

Cabaletta Bio Trading Down 0.9 %

Shares of NASDAQ:CABA traded down $0.01 during midday trading on Thursday, reaching $1.14. The company had a trading volume of 309,991 shares, compared to its average volume of 1,492,969. The stock has a market cap of $57.59 million, a P/E ratio of -0.53 and a beta of 2.44. The company's 50 day moving average price is $1.95 and its 200 day moving average price is $2.84. Cabaletta Bio has a 52-week low of $0.99 and a 52-week high of $19.04.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.65) earnings per share for the quarter, hitting the consensus estimate of ($0.65).

Hedge Funds Weigh In On Cabaletta Bio

Hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Cabaletta Bio during the 3rd quarter valued at about $32,000. Point72 DIFC Ltd purchased a new position in Cabaletta Bio during the third quarter valued at approximately $33,000. Miller Financial Services LLC bought a new stake in Cabaletta Bio during the 4th quarter worth approximately $33,000. Avanza Fonder AB purchased a new stake in Cabaletta Bio in the 4th quarter worth approximately $40,000. Finally, Intech Investment Management LLC raised its position in shares of Cabaletta Bio by 42.2% in the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company's stock worth $46,000 after buying an additional 5,999 shares in the last quarter.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.